[The efficacy of foridon in treating stenocardia patients]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Exertional stenocardia presents significant challenges in managing pain and cardiovascular function.
• Existing treatments like phynoptin and corinfar serve as benchmarks for new therapeutic agents.

Purpose of the Study:

• To evaluate the efficacy of a novel native calcium antagonist, foridon, in patients with exertional stenocardia.
• To assess foridon's impact on various physiological markers including hemodynamics, metabolism, and immune status.

Main Methods:

• A comparative study involving 30 patients with exertional stenocardia treated with foridon.
• A control group of 30 patients received standard treatment with phynoptin and corinfar.
• Comprehensive monitoring of central and peripheral hemodynamics, lipid metabolism, oxidative stress markers, and immune parameters.

Main Results:

• Foridon demonstrated a positive effect on reducing the intensity of the pain syndrome in stenocardia patients.
• Significant improvements were observed in hemodynamic parameters following foridon treatment.
• The study noted beneficial effects on lipid peroxidation, cyclic nucleotide levels, and the immune status of patients.

Conclusions:

• Foridon shows promise as an effective therapeutic agent for managing exertional stenocardia.
• The novel calcium antagonist positively influences key indicators of cardiovascular health and disease progression.